ALS News Today30m
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Managed Healthcare Executive49m
Novel Therapy Prevents Skin Cancer by Training Immune System’s Helper Cells
A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...